Laekna and Lilly Partner to Develop Obesity Treatment Antibody LAE102
Laekna, Inc. (2105.HK) (“Laekna”), an international biotechnology firm dedicated to the advancement of new therapeutics for metabolic and oncological disorders, is excited to reveal a clinical partnership with Eli Lilly and Company (Lilly), a worldwide frontrunner in cardiometabolic healthcare, particularly in diabetes and obesity management. This collaboration aims to expedite the progress of LAE102, a novel ActRIIA monoclonal antibody designed as a potential treatment for obesity. The goal of such innovative therapies is to significantly address the obesity crisis and improve the quality of life for millions impacted by this condition.
👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.
Clinical advancement of LAE102 through a phase 1 trial involving obese participants
Lilly will provide funding, along with shared resources and expertise, to expedite the research and development processes.Laekna holds global rights to LAE102.
The partnership will concentrate on the clinical development and assessment of LAE102, a novel ActRIIA antagonistic mAb that has the potential to become a pioneering treatment in this therapeutic area. ActRIIA is a receptor that plays a significant role in muscle regeneration and lipid metabolism. Pre-clinical studies have demonstrated that LAE102 can enhance lean mass and reduce fat mass. If the trial is successful, LAE102 could, when paired with a GLP1R agonist, further decrease fat mass while significantly recovering the lean mass loss attributed to the GLP1R agonist. This positions LAE102 as a promising adjunctive candidate for effective weight management.
By integrating Laekna’s innovative strategies with Lilly’s extensive experience in metabolic disorders, this collaboration aims to enhance the standard of care in the treatment of obesity.
“We are excited to partner with the exceptional team at Lilly, a leading global authority in obesity and metabolic conditions, to bring advanced therapies to patients grappling with this challenging issue,” stated Dr. Chris Lu, Chairman and Chief Executive Officer of Laekna. “Together with Lilly’s extensive clinical knowledge in the cardiometabolic arena, we are hopeful about the potential of this collaboration to expedite the worldwide development of LAE102 and positively influence the lives of millions affected by obesity.”
👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!
According to the data provided by the Synapse Database, As of November 26, 2024, there are 10 investigational drug for the ACVR2A target, including 68 indications, 19 R&D institutions involved, with related clinical trials reaching 64, and as many as 2508 patents.
LAE-102 is a monoclonal antibody drug developed by Laekna Therapeutics (Shanghai) Co., Ltd. The drug targets ACVR2A and is being developed for the treatment of various therapeutic areas including Endocrinology and Metabolic Disease, Neoplasms, and Respiratory Diseases. The active indications for which LAE-102 is being studied include Obesity, Overweight, Metastatic Solid Tumor, and Non-Small Cell Lung Cancer.
